Home | Neuromuscular | Duchenne muscular dystrophy (DMD) | Congress activities | American Academy of Neurology Annual Meeting (AAN) | AAN 2023 oral presentation: Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial

AAN 2023 oral presentation: Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial

This AAN 2023 oral presentation focused on ataluren use for the treatment of nonsense mutation Duchene muscular dystrophy (nmDMD) patients. The symposium detailed the efficacy and safety profile of ataluren in Study 041

  • Appreciate the trial design and patient characteristics in Study 041
  • Explore the efficacy of ataluren in nmDMD across multiple motor endpoints
  • Understand the safety profile of ataluren in nmDMD

▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.

This oral presentation was developed and funded by PTC Therapeutics for AAN 2023.

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

Registration
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

    *
    *
  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

MED-ALL-DMD-2300168 | September 2023
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | October 2023

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.